Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
To determine the pharmacokinetic profile and to evaluate the safety and tolerability of
ascending multiple doses of tigecycline in patients aged 8 to 11 years with selected serious
infections; complicated intra-abdominal infections (cIAI), complicated skin and skin
structure infections (cSSSI), or community-acquired pneumonia (CAP).